TriMarc Laboratories offers a proprietary line of prescription and Over the Counter (OTC) medications acquired or formulated to meet the needs of the healthcare industry. Currently TriMarc is focused on dermatology and skin care products, while offering an OTC line of prenatal and joint supplements, topical rubs, and sexually enhancement products. TriMarc seeks to develop or acquire additional products, formulations and technologies to meet our long terms goals as an ethical pharmaceutical firm. TriMarc offers a national marketing and distribution team that covers the US, while seeking additional affiliates and direct marketing teams to compliment our efforts to grow and be recognized as a leader in the pharmaceutical market. TriMarc seeks to launch several new products each year and continues to build our pipeline of medications through selective research and successful business relationship. TriMarc Laboratories is open to in-licensing and out-licensing programs that meet our marketing strategies or fulfills our portfolio of products for domestic or international markets.
| Website | http://www.trimarclabs.com |
| Revenue | $5.2 million |
| Employees | View employees |
| Address | 727 N Ann Arbor Ave, Oklahoma City, Oklahoma 73127, US |
| Phone | +1 405-942-3289 |
| Industry | Manufacturing General, Manufacturing |
| Competitors | Thermo Fisher Scientific, Bio-Techne, abcam, R&D Systems, BioLegend, Cell Signaling Technology (CST), MilliporeSigma, Santa Cruz Biotechnology (SCBT), Invitrogen, PEPROTECH EC LTD +42 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular TriMarc Laboratories employee's phone or email?
The TriMarc Laboratories annual revenue was $5.2 million in 2026.
TriMarc Laboratories is based in Oklahoma City, Oklahoma.
The NAICS codes for TriMarc Laboratories are [32541, 325, 32, 3254].
The SIC codes for TriMarc Laboratories are [283, 28].